Posted by Michael Wonder on 29 Mar 2022
Santhera and ReveraGen start rolling NDA submission to the FDA for vamorolone for the treatment of Duchenne muscular dystrophy
29 March 2022 - Santhera Pharmaceuticals and ReveraGen BioPharma announce the initiation of a rolling new drug application submission to the U.S. FDA for vamorolone for the treatment of Duchenne muscular dystrophy.
Vamorolone for Duchenne muscular dystrophy has been granted fast track designation by the FDA.
